Milestone Pharmaceuticals (MIST) Cash from Investing Activities (2018 - 2026)

Milestone Pharmaceuticals' Cash from Investing Activities history runs 9 years deep, the most recent figure standing at -$80.0 million for Q1 2026.

• Quarterly Cash from Investing Activities fell 338.31% year-over-year to -$80.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$102.4 million (down 248.62% YoY) and the FY2025 annual result came in at $11.2 million, up 35.77% from the prior year.
• Cash from Investing Activities was -$80.0 million for Q1 2026 at Milestone Pharmaceuticals, down from $2.7 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $33.6 million in Q1 2025 and bottomed at -$80.0 million in Q1 2026.
• A 5-year average of -$6.6 million and a median of -$8.0 million in 2022 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities surged 474.6% — and 2025, when it plunged 639.79%.
• Milestone Pharmaceuticals' Cash from Investing Activities stood at -$17.0 million in 2022, then surged by 180.38% to $13.7 million in 2023, then surged by 41.37% to $19.3 million in 2024, then plunged by 86.02% to $2.7 million in 2025, then plunged by 3060.78% to -$80.0 million in 2026.
• Business Quant data shows MIST's Cash from Investing Activities at -$80.0 million in Q1 2026, $2.7 million in Q4 2025, and -$35.0 million in Q3 2025.